Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate
The possibility of correction of morphological changes in the myocardium and biochemical parameters of the blood with 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg was studied in the model of doxorubicin-induced chronic heart failure in rats. It was found that 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg produced less pronounced cardio-protective effect in experimental chronic heart failure than 3-hydroxypyridine succinate.
Key Wordsregenerative and plastic heart failure 3-hydroxypyridine acetylcysteinate
Unable to display preview. Download preview PDF.
- 1.Andreeva NN. The experimental and clinical aspects of the application of Meksidol in hypoxia. Med. Al’manakh. 2009;(4):193-197. Russian.Google Scholar
- 3.Vereshchagina GN, Irkhina IS, Ermakova ÉN, Poltaranina GG, Novikova ON. Mexidol in scheme of combined therapy of chronic heart failure of the 2nd-3nd functional classes. Kardiol. Serd.-Sosud. Khirurgiya. 2013;6(6):60-63. Russian.Google Scholar
- 4.Vladimirov YuA, Archkov AI. Lipid Peroxidation in Biological Membranes. Moscow, 1972. Russian.Google Scholar
- 6.Zamotaeva MN, Inchina VI, Chairkin IN, Drozdov IA, Kuzmichev ND, Kuznetsov YuV. A comparative study of cardioprotective properties of succinate 3-oxipiridine and acetylcisteinate 3-oxipiridine at experimental chronical heart deficiency. Sovremen. Probl. Nauki Obrazovaniya. 2013;(4):140. Russian.Google Scholar
- 7.Zamotaeva MN, Inchina VI, Chairkin IN, Drozdov IA, Kuzmichev ND, Kuznetsov YV. A comparative analysis of 3-oxypiridine succinate and 3-oxypiridine acetylcisteinate cardioprotactive properties at experimental acute myocardium infarction. Fundamental. Issled. 2013;(12-3):479-482. Russian.Google Scholar
- 8.Inchina VI, Vintin NA, Zor’kina AV, Sernov LN, Kostin YaV. Pharmacological rehabilitation under conditions of long-term restrain stress. Mezhdunarod. Zh. Immunoreab. 1996;(2):90. Russian.Google Scholar
- 9.Korolyuk MA, Ivanova LI, Maiorova IG, Tokarev VE. A method for measuring catalase activity. Lab. Delo. 1988;(1):16-19. Russian.Google Scholar
- 10.Litvitskii PF. Pathogenetic and adaptive changes in the heart during its regional ischemia followed by coronary blood flow resumption. Patol. Fiziol. 2002;(2):2-12. Russian.Google Scholar
- 11.Luk’yanova LD. Mitochondrial dysfunction is a typical pathological process and molecular mechanism of hypoxia. Problems of Hypoxia: Molecular, Physiological, and Medical Aspects. Luk’yanova LD, Ushakov IB, eds. Moscow; Voronezh, 2004. P. 8-50. Russian.Google Scholar
- 12.Maksimovich NE, Zinchuk VV, Maslakov DA. The intensity of oxidative stress in rat brain during ischemia/reperfusion under conditions of correction of L-arginine-NO-system. Ross. Fiziol. Zh. 2005;91(4):385-393. Russian.Google Scholar
- 13.Syrkin AL, Dobrovol’skii AV. Metabolism corrector anti-ischemic drugs. Consilium Medicum. 2002;4(11):572-575. Russian.Google Scholar
- 14.De Windt LJ, Willems J, Roemen TH, Coumans WA, Reneman RS, Van Der Vusse GJ, Van Bilsen M. Ischemic: reperfused isolated working mouse heart: membrane damage and type II A phospholipase A. Am. J. Physiol. Heart Cirс. Physiol. 2001;280(6):H2572-H2580.Google Scholar